中西药合用治疗肿瘤的相互作用及其机制探讨

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (2): 134-139.

中西药合用治疗肿瘤的相互作用及其机制探讨

范岚¹, 谢海棠^1,2, 周宏灏¹

¹中南大学临床药理研究所, 长沙 410078, 湖南;
²安徽省药物临床评价中心, 芜湖 241001, 安徽

收稿日期:2007-02-02 修回日期:2007-03-02 出版日期:2007-02-26 发布日期:2020-10-27
通讯作者: 周宏灏, 男, 教授, 博导, 主要从事遗传药理和临床药理学研究。Tel:0731-4804028 　E-mai l:hhzhou2003 @163.com
作者简介:范岚, 女, 博士, 主要从事遗传药理和临床药理学研究。
基金资助:
国家自然科学基金(30572225); China Medical Board 01-755; 湖南省卫生厅科研基金(204041); 中国卫生部重点科学技术创新培养基金(704036) 资助课题

Herb-drug interactions in oncology and potential mechanisms

FAN Lan¹, XIE Hai-tang^1,2, ZHOU Hong-hao¹

¹Institute of Clinical Pharmacology, Central South University, Changsha 410078, Hunan, China;
²Anhui Provincial Center for Drug Clinical Evaluation, Wuhu 241001, Anhui, China

Received:2007-02-02 Revised:2007-03-02 Online:2007-02-26 Published:2020-10-27

摘要/Abstract

摘要： 如今, 越来越多的肿瘤患者在接受传统化疗的同时服用中药作为替代补充治疗的手段。由于抗肿瘤药物的治疗窗通常都比较狭窄, 中药的合用增加了临床上中西药发生相互作用和不良反应的风险, 导致化疗药物对病患疗效不佳或产生毒性反应。本文综述了目前已知用于肿瘤治疗的中西药在药物代谢动力学上的相互作用, 以及发生相互作用的潜在机制。

关键词: 中西药相互作用, 化疗, 诱导, 抑制, 药物代谢

Abstract: An increasing number of cancer patients are using complementary and alternative medicines (CAM) in combination with their conventional chemotherapeutic treatment.Considering the narrow therapeutic window of oncolytic drugs, this CAM use increases the risk of clinically relevant herb-anticancer drug interactions, therefore leading to substantially more unexpected toxicities of chemotherapeutic drugs and possible undertreatment seen in cancer patients.This review provides information about currently known, clinically relevant PK CAM-drug interactions in oncology and the potential mechanisms.

Key words: herb-drug interactions, chemotherapeutics, induction, inhibition, drug metabolism

中图分类号:

R730.59

范岚, 谢海棠, 周宏灏. 中西药合用治疗肿瘤的相互作用及其机制探讨[J]. 中国临床药理学与治疗学, 2007, 12(2): 134-139.

FAN Lan, XIE Hai-tang, ZHOU Hong-hao. Herb-drug interactions in oncology and potential mechanisms[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 134-139.

参考文献

[1] Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John' s wort on irinotecan metabolism[J]. J Natl Cancer Inst,2002;94:1247-1249.
[2] Harkey MR, Henderson GL, GershwinME, et al. Variability in commercial ginseng products:An analy sis of 25 preparations[J]. Am J Clin Nutr, 2001;73:1101-1106.
[3] BlumenthalM.Herbs continue slide in mainstream market:Sales down 14 percent[J]. Herbal Gram, 2003;58:71.
[4] Reif S, Nicolson MC, Bisset D, et al. Effect of grapefruit juice intake on etoposide bioavailability[J]. Eur J Clin Pharmacol,2002;58:491-494.
[5] Gurley BJ, Gardner SF, HubbardMA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans[J]. Clin Pharmacol Ther, 2002;72:276-287.
[6] Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir[J]. Clin Infect Dis, 2002;34:234-238.
[7] Gallicano K, Foster B, Choudhri S.Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers[J]. Br J Clin Pharmacol, 2003;55:199-202.
[8] Smith M, Lin KM, Zheng YP.An open trial of nifedipine-herb interactions:Nifedipine with St.John' s wort, ginseng or Ginkgo biloba[J]. Clin Pharmacol Ther, 2001;69:P86.
[9] Sun HF, Zuo Z, Yin OQ, et al. A “highthroughput” cocktail method for screening the effect of herbal product on liver isozyme activities:Experience with Ginkgo biloba[J]. Clin Pharmacol Ther, 2002;71:P100.
[10] Weiger W, Smith MR, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer[J]. Ann Intern Med, 2002;137:889-903.
[11] Gorski JG, Huang SM, Pinto A, et al. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo[J]. Clin Pharmacol Ther, 2004;75:89-100.
[12] Kivisto KT, Kroemer HK, Eichelbaum M.The role of human cytochrome P450 enzymes in the metabolism of anticancer agents:Implications for drug interactions[J]. Br J Clin Pharmacol,1995;40:523-530.
[13] Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A mediated metabolism[J]. Adv Drug Deliv Rev, 2002;54:1271-1294.
[14] Peebles KA, Baker RK, Kurz EU, et al. Catalytic inhibition of human DNA topoisomerase II alpha by hypericin, a naphthodianthrone from St.John' s wort (Hypericum perforatum)[J]. Biochem Pharmacol, 2001;62:1059-1070.
[15] Mansky PJ, Straus SE.St.John' s Wort:More implications for cancer patients[J]. J Natl Cancer Inst, 2002;94:1187-1188.
[16] Beijnen JH, Schellens JH.Drug interactions in oncology[J]. Lancet Oncol, 2004;5:489-496.
[17] Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy[J]. Drug Resist Updat, 2003;6:71-84.
[18] Bosch TM, Meijerman I, Beijnen JH, et al. Genetic polymorphisms of drug metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer[J]. Clin Pharmacokinet,2006;45:253-285.
[19] Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States:potential adverse interactions with anticancer agents[J]. J Clin Oncol, 2004;22:2489-2503.
[20] Schinkel AH, Jonker JW.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family:an overview[J]. Adv Drug Deliv Rev, 2003;55:3-29.
[21] RichardsonMA, Sanders T, Palmer JL, et al. Complementary alternative medicine use in a comprehensive cancer center and the implications for oncology[J]. J Clin Oncol, 2000;18:2505-2514.
[22] Liu JM, Chu HC, Chin YH, et al. Cross sectional study of use of alternative medicines in Chinese cancer patients[J]. Jpn J Clin Oncol, 1997;27:37-41.
[23] Broxterman HJ, Lankelma J, Hoekman K.Resistance to cytotoxic and anti-angiogenic anticancer agents:Similarities and differences[J]. Drug Resist Updat, 2003;6:111-127.
[24] Zou L, Harkey MR, Henderson GL.Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity[J]. Life Sci, 2002;71:1579-1589.
[25] Yale SH, Glurich I.Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9[J]. J Altern Complement Med, 2005;11:433-439.
[26] Henderson GL, Harkey MR, Gershwin ME, et al. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity[J]. Life Sci, 1999;65:209-214.
[27] Sridar C, Goosen TC, Kent UM, et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosy ltransferases[J]. Drug Metab Dispos, 2004;32:587-594.
[28] Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosy l transferase in human hepatocyte cultures[J]. Drug Metab Dispos, 2000;28:1270-1273.
[29] Zuber R, Modriansky M, Dvorak Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities[J]. Phytother Res, 2002;16:632-638.
[30] Zhou S, Lim LY, Chowbay B.Herbal modulation of P-glycoprotein[J]. Drug Metab Rev, 2004;36:57-104.
[31] Zhang S, Morris ME.Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells[J]. Pharm Res, 2003;20:1184-1191.
[32] Limtrakul P, Khantamat O, Pintha K.Inhibition of P-glycoprotein function and expression by kaempferol and quercetin[J]. J Chemother, 2005;17:86-95.
[33] Imai Y, Tsukahara S, Asada S, et al. Phytoestrogens flavonoids reverse breast cancer resistance protein ABCG2-mediated multidrug resistance[J]. Cancer Res, 2004;64:4346-4352.
[34] Zhang S, Yang X, Morris ME.Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport[J]. Mol Pharmacol, 2004;65:1208-1216.
[35] Mangelsdorf DJ, Evans RM.The RXR heterodimers and orphan receptors[J]. Cell, 1995;83:841-850.
[36] Blumberg B, Sabbagh WJ, Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor[J]. Genes Dev, 1998;12:3195-3205.
[37] 孟勇. 抗癌中药的研究进展[J]. 医学理论与实践, 2006;19:1153-1154.
[38] 王庆才. 中医药在肿瘤综合治疗中的作用[J]. 中医药管理杂志, 2006;14:59-60.
[39] Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes:Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto[J]. Clin Pharmacol Ther, 2004;76:428-440.
[40] McLeod HL.Clinically relevant drug-drug interactions in oncology[J]. Br J Clin Pharmacol, 1998;45:539-544.